NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for severe CNS disorders — primarily suicidal depression, bipolar depression, and PTSD — alongside a growing network of interventional psychiatry clinics. NRx operates two arms: a drug development business (NRx/NeuroRx) and a clinic delivery subsidiary (HOPE Therapeutics). On the drug side, NRx has three candidates. KETAFREE is a preservative-free IV ketamine formulation pursuing generic FDA approval (ANDA), targeting the ~$750M generic ketamine market. NRX-100 is an NDA-track branded IV ketamine product targeting suicidal ideation — an indication with no currently approved therapy and one that J&J's SPRAVATO explicitly does not claim to treat. NRX-101 is an oral fixed-dose combination of D-cycloserine and lurasidone targeting suicidal bipolar depression, holding FDA Breakthrough Therapy Designation. NRx's drug commercialization strategy relies on a lean salesforce targeting concentrated prescriber bases, and NRx has received non-binding partnership interest for NRX-100 structured as milestone payments and royalties. HOPE Therapeutics is a wholly-owned clinic network offering integrated neuroplastic therapies — IV ketamine, TMS, hyperbaric therapy, and medication management — currently operating five Florida locations with expansion planned. NRx intends to eventually spin HOPE out as a standalone public company, funding acquisitions through debt and private equity rather than NRx equity.